AcceXible Speech Analysis for MCI Detection in Colombia NCT07553117
Summary
This NCT07553117 observational study, registered April 27, 2026, evaluates the diagnostic performance of AcceXible, a speech analysis-based machine learning platform, for detecting Mild Cognitive Impairment (MCI) in Colombian patients at EPS Sanitas primary care settings. The study pursues two primary aims: validating the AcceXible tool in a Colombian population and demonstrating high diagnostic accuracy relative to the Montreal Cognitive Assessment (MoCA) for early MCI detection and longitudinal monitoring. The study is conducted by clinical investigators within Colombia's healthcare system and represents a diagnostic test accuracy study in a primary care setting.
“This study evaluates the diagnostic performance of AcceXible, a speech analysis-based machine learning platform, compared to the Montreal Cognitive Assessment (MoCA) for MCI detection and monitoring in Colombian patients.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
This clinical trial registration documents an observational diagnostic accuracy study evaluating AcceXible, a speech analysis-based machine learning platform, against the Montreal Cognitive Assessment for Mild Cognitive Impairment detection in Colombian patients. The study will be conducted at EPS Sanitas, a Colombian primary care provider, and includes prior validation of the AcceXible protocol in the Colombian healthcare context. Two primary aims are pursued: validating the tool in the target population and demonstrating high diagnostic accuracy for early detection and longitudinal monitoring. Clinical investigators conducting MCI research and healthcare providers in Colombia may find this study relevant for understanding emerging AI-based diagnostic approaches in primary care settings.
Archived snapshot
Apr 27, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Accexible Speech Analysis for MCI Detection and Monitoring in Colombia
Observational NCT07553117 Kind: OBSERVATIONAL Apr 27, 2026
Abstract
Mild Cognitive Impairment (MCI) is frequently underdiagnosed due to its subtle clinical presentation. This study evaluates the diagnostic performance of AcceXible, a speech analysis-based machine learning platform, compared to the Montreal Cognitive Assessment (MoCA) for MCI detection and monitoring in Colombian patients.
A diagnostic test accuracy study will be conducted within a primary care setting (EPS Sanitas), including prior validation of the AcceXible protocol in the Colombian healthcare context.
The study pursues two primary aims: (1) to validate the AcceXible tool in a Colombian population, and (2) to demonstrate that AcceXible achieves high diagnostic accuracy for early MCI detection and longitudinal monitoring relative to the MoCA.
Conditions: MCI
Interventions: Accexible
Parties
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.